Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026)

Sarepta Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $499.2 million for Q1 2026.

• In Q1 2026, Total Current Liabilities fell 17.57% year-over-year to $499.2 million; the TTM figure through Mar 2026 stood at $499.2 million (down 17.57% YoY), while the FY2025 annual figure was $1.1 billion, up 49.69% from the prior year.
• Total Current Liabilities was $499.2 million for Q1 2026 at Sarepta Therapeutics, down from $1.1 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $1.1 billion in Q4 2025 to a low of $450.7 million in Q3 2023.
• Historically, Total Current Liabilities has averaged $654.9 million across 5 years, with a median of $608.7 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities jumped 61.45% in 2022, then dropped 25.24% in 2023.
• A 5-year view of Total Current Liabilities shows it stood at $619.6 million in 2022, then rose by 5.5% to $653.7 million in 2023, then gained by 11.94% to $731.7 million in 2024, then jumped by 49.69% to $1.1 billion in 2025, then plunged by 54.43% to $499.2 million in 2026.
• The last three Total Current Liabilities figures came in at $499.2 million (Q1 2026), $1.1 billion (Q4 2025), and $921.4 million (Q3 2025), per Business Quant data.